|
1
|
American Cancer Society, . Cancer Facts
& Figures 2020. Am Cancer Soc. 1–52. 2020.
|
|
2
|
Meltzer PS and Helman LJ: New horizons in
the treatment of osteosarcoma. N Engl J Med. 385:2066–2076. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Corre I, Verrecchia F, Crenn V, Redini F
and Trichet V: The osteosarcoma microenvironment: A complex but
targetable ecosystem. Cells. 9:9762020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gill J and Gorlick R: Advancing therapy
for osteosarcoma. Nat Rev Clin Oncol. 18:609–624. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Belayneh R, Fourman MS, Bhogal S and Weiss
KR: Update on osteosarcoma. Curr Oncol Rep. 23:712021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shoaib Z, Fan TM and Irudayaraj JMK:
Osteosarcoma mechanobiology and therapeutic targets. Br J
Pharmacol. 179:201–217. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sheng G, Gao Y, Yang Y and Wu H:
Osteosarcoma and metastasis. Front Oncol. 11:7802642021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brede G, Solheim J and Prydz H: PSKH1, a
novel splice factor compartment-associated serine kinase. Nucleic
Acids Res. 30:5301–5309. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brede G, Solheim J, Tröen G and Prydz H:
Characterization of PSKH1, a novel human protein serine kinase with
centrosomal, golgi, and nuclear localization. Genomics. 70:82–92.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim ST, Ahn TJ, Lee E, Do IG, Lee SJ, Park
SH, Park JO, Park YS, Lim HY, Kang WK, et al: Exploratory biomarker
analysis for treatment response in KRAS wild type metastatic
colorectal cancer patients who received cetuximab plus irinotecan.
BMC Cancer. 15:7472015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Whitworth H, Bhadel S, Ivey M, Conaway M,
Spencer A, Hernan R, Holemon H and Gioeli D: Identification of
kinases regulating prostate cancer cell growth using an RNAi
phenotypic screen. PLoS One. 7:e389502012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Zhang S, Yin J and Xu R: MiR-566
mediates cell migration and invasion in colon cancer cells by
direct targeting of PSKH1. Cancer Cell Int. 19:3332019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu H, Zou D, Ni N, Zhang S, Zhang Q and
Yang L: Overexpression of NCAPG in ovarian cancer is associated
with ovarian cancer proliferation and apoptosis via p38 MAPK
signaling pathway. J Ovarian Res. 15:982022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu M, Zhou J, Liu X, Feng Y, Yang W, Wu
F, Cheung OK, Sun H, Zeng X, Tang W, et al: Targeting
monocyte-intrinsic enhancer reprogramming improves immunotherapy
efficacy in hepatocellular carcinoma. Gut. 69:365–379. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puri PL, Wu Z, Zhang P, Wood LD, Bhakta
KS, Han J, Feramisco JR, Karin M and Wang JY: Induction of terminal
differentiation by constitutive activation of p38 MAP kinase in
human rhabdomyosarcoma cells. Genes Dev. 14:574–584. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J,
Pan T, Yu KJ, Liu B, Creighton CJ, Rodriguez-Canales J, et al:
Osteoblast-secreted factors mediate dormancy of metastatic prostate
cancer in the bone via activation of the
TGFβRIII-p38MAPK-pS249/T252RB pathway. Cancer Res. 78:2911–2924.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Comes F, Matrone A, Lastella P, Nico B,
Susca FC, Bagnulo R, Ingravallo G, Modica S, Lo Sasso G, Moschetta
A, et al: A novel cell type-specific role of p38alpha in the
control of autophagy and cell death in colorectal cancer cells.
Cell Death Differ. 14:693–702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Igea A and Nebreda AR: The stress kinase
p38α as a target for cancer therapy. Cancer Res. 75:3997–4002.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kumar VB, Lin SH, Mahalakshmi B, Lo YS,
Lin CC, Chuang YC, Hsieh MJ and Chen MK: Sodium danshensu inhibits
oral cancer cell migration and invasion by modulating p38 signaling
pathway. Front Endocrinol (Lausanne). 11:5684362020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gerdes J, Li L, Schlueter C, Duchrow M,
Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E and Flad HD:
Immunobiochemical and molecular biologic characterization of the
cell proliferation-associated nuclear antigen that is defined by
monoclonal antibody Ki-67. Am J Pathol. 138:867–873.
1991.PubMed/NCBI
|
|
22
|
Gerdes J, Lemke H, Baisch H, Wacker HH,
Schwab U and Stein H: Cell cycle analysis of a cell
proliferation-associated human nuclear antigen defined by the
monoclonal antibody Ki-67. J Immunol. 133:1710–1715. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rioux-Leclercq N, Turlin B, Bansard J,
Patard J, Manunta A, Moulinoux JP, Guillé F, Ramée MP and Lobel B:
Value of immunohistochemical Ki-67 and p53 determinations as
predictive factors of outcome in renal cell carcinoma. Urology.
55:501–505. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krishna OH, Kayla G, Abdul Aleem M,
Malleboyina R and Reddy Kota R: Immunohistochemical expression of
Ki67 and p53 in wilms tumor and its relationship with tumor
histology and stage at presentation. Patholog Res Int.
2016:61239512016.PubMed/NCBI
|
|
25
|
Dudderidge TJ, Stoeber K, Loddo M,
Atkinson G, Fanshawe T, Griffiths DF and Williams GH: Mcm2,
Geminin, and KI67 define proliferative state and are prognostic
markers in renal cell carcinoma. Clin Cancer Res. 11:2510–2517.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shi W, Hu J, Zhu S, Shen X, Zhang X, Yang
C, Gao H and Zhang H: Expression of MTA2 and Ki-67 in
hepatocellular carcinoma and their correlation with prognosis. Int
J Clin Exp Pathol. 8:13083–13089. 2015.PubMed/NCBI
|
|
27
|
Kankuri M, Söderström KO, Pelliniemi TT,
Vahlberg T, Pyrhönen S and Salminen E: The association of
immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of
metastases and survival in renal cell carcinoma. Anticancer Res.
26:3825–3833. 2006.PubMed/NCBI
|
|
28
|
Zeng M, Zhou J, Wen L, Zhu Y, Luo Y and
Wang W: The relationship between the expression of Ki-67 and the
prognosis of osteosarcoma. BMC Cancer. 21:2102021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Evangelisti C, Paganelli F, Giuntini G,
Mattioli E, Cappellini A, Ramazzotti G, Faenza I, Maltarello MC,
Martelli AM, Scotlandi K, et al: Lamin A and Prelamin A counteract
migration of osteosarcoma cells. Cells. 9:7742020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Niu G, Ye T, Qin L, Bourbon PM, Chang C,
Zhao S, Li Y, Zhou L, Cui P, Rabinovitz I, et al: Orphan nuclear
receptor TR3/Nur77 improves wound healing by upregulating the
expression of integrin β4. FASEB J. 29:131–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi B, Xue M, Wang Y, Wang Y, Li D, Zhao X
and Li X: An improved method for increasing the efficiency of gene
transfection and transduction. Int J Physiol Pathophysiol
Pharmacol. 10:95–104. 2018.PubMed/NCBI
|
|
35
|
Xiang B, Geng R, Zhang Z, Ji X, Zou J,
Chen L and Liu J: Identification of the effect and mechanism of
Yiyi Fuzi Baijiang powder against colorectal cancer using network
pharmacology and experimental validation. Front Pharmacol.
13:9298362022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi D, Wu F, Mu S, Hu B, Zhong B, Gao F,
Qing X, Liu J, Zhang Z and Shao Z: LncRNA AFAP1-AS1 promotes
tumorigenesis and epithelial-mesenchymal transition of osteosarcoma
through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway. J Exp Clin
Cancer Res. 38:3752019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fan MK, Zhang GC, Chen W, Qi LL, Xie MF,
Zhang YY, Wang L and Zhang Q: Siglec-15 promotes tumor progression
in osteosarcoma via DUSP1/MAPK pathway. Front Oncol. 11:7106892021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia Y, Khoi PN, Yoon HJ, Lian S, Joo YE,
Chay KO, Kim KK and Jung YD: Piperine inhibits IL-1β-induced IL-6
expression by suppressing p38 MAPK and STAT3 activation in gastric
cancer cells. Mol Cell Biochem. 398:147–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Niu J, Yan T, Guo W, Wang W, Zhao Z, Ren
T, Huang Y, Zhang H, Yu Y and Liang X: Identification of potential
therapeutic targets and immune cell infiltration characteristics in
osteosarcoma using bioinformatics strategy. Front Oncol.
10:16282020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M,
Qin Y, Sun K, Teng Y and Liu M: Cancer-associated fibroblast
(CAF)-derived IL32 promotes breast cancer cell invasion and
metastasis via integrin β3-p38 MAPK signalling. Cancer Lett.
442:320–332. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ni S, Li J, Qiu S, Xie Y, Gong K and Duan
Y: KIF21B expression in osteosarcoma and its regulatory effect on
osteosarcoma cell proliferation and apoptosis through the PI3K/AKT
pathway. Front Oncol. 10:6067652021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Jiang QG, Xiong CF and Lv YX: Kin17
facilitates thyroid cancer cell proliferation, migration, and
invasion by activating p38 MAPK signaling pathway. Mol Cell
Biochem. 476:727–739. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fang Y, Yang J, Zu G, Cong C, Liu S, Xue
F, Ma S, Liu J, Sun Y and Sun M: Junctional adhesion molecule-like
protein promotes tumor progression and metastasis via p38 signaling
pathway in gastric cancer. Front Oncol. 11:5656762021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Saraf AJ, Fenger JM and Roberts RD:
Osteosarcoma: Accelerating progress makes for a hopeful future.
Front Oncol. 8:42018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Z, Wang Z, Li B, Wang S, Chen T and
Ye Z: Innate immune cells: A potential and promising cell
population for treating osteosarcoma. Front Immunol. 10:11142019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Chen C, Xie L, Ren T, Huang Y, Xu J and
Guo W: Immunotherapy for osteosarcoma: Fundamental mechanism,
rationale, and recent breakthroughs. Cancer Lett. 500:1–10. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Whelan JS and Davis LE: Osteosarcoma,
chondrosarcoma, and chordoma. J Clin Oncol. 36:188–193. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Gianferante DM, Mirabello L and Savage SA:
Germline and somatic genetics of osteosarcoma-connecting aetiology,
biology and therapy. Nat Rev Endocrinol. 13:480–491. 2017.
View Article : Google Scholar : PubMed/NCBI
|
